10X Genomics Inc Environmental Analytics
Environmental and financial analysis dashboard for 10X Genomics Inc. Industry: MANUFACTURING
Company Overview for 10X Genomics Inc
Highlights
Showing data for FY2022
Operational Environmental Cost
$1.35m
Operational Environmental Cost Intensity
0.26%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$0.59m
Decoupling Rate (2020-2022)
-1.73%
Adjusted EBITDA
$-130m
Adjusted EBITDA Margin
-25%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 82.36% | 8.69% | 2.86% | ||
| 0.05% | 0.05% | 0.05% | 0.05% | |
| 80.74% | -3.43% | 17.58% | ||
| 0.21% | 0.23% | 0.21% | 0.20% | |
| $1m | $1m | $1m | $2m | |
| 81.03% | -1.21% | 14.61% | ||
| 0.25% | 0.28% | 0.26% | 0.25% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
-25%
Adjusted EBIT Margin
-32%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$299m | $491m | $516m | $619m | |
| 64.26% | 5.20% | 19.81% | ||
$813m | $516m | $645m | $824m | |
| 271.92% | 105.01% | 124.88% | 133.15% | |
$-514m | $-25m | $-128m | $-205m | |
| -171.92% | -5.01% | -24.88% | -33.15% | |
$-533m | $-53m | $-161m | $-249m | |
| -178.28% | -10.77% | -31.27% | -40.20% | |
| ENVIRONMENTAL COST DATA | ||||
$1m | $1m | $1m | $2m | |
| 0.25% | 0.28% | 0.26% | 0.25% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$-515m | $-26m | $-130m | $-207m | |
| -172.17% | -5.29% | -25.14% | -33.40% | |
$-534m | $-54m | $-163m | $-250m | |
| -178.54% | -11.05% | -31.53% | -40.45% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.05%
Scope 2 (% of Sales)
0.21%
Operational Environmental Cost Intensity
0.26%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
10X Genomics Inc | US | $1m | 0.26% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022